Endoscopic Treatment of Gastroesophageal Reflux Disease
Study Details
Study Description
Brief Summary
Gastroesophageal reflux disease (GERD) occurs when stomach acid repeatedly flows back into the tube connecting your mouth and stomach (esophagus). This backwash (acid reflux) can irritate the inner lining of the esophagus.
The goal of this small clinical trial is to examine the effect of endoscopic treatment of
GERD by mucosal band ligation. The main questions it aims to answer are:
-
Does the treatment affect gastroesophageal reflux assessed by measuring gastroesophageal reflux
-
Does the treatment affect gastroesophageal reflux symptoms and ability to stop treatment with medication commonly used (proton pump inhibitors)
Participants (n=12) will be asked to undergo 24 h reflux examination and report symptoms of GERD. Suitable patients will be offered endoscopic treatment with band ligation of the inner lining of the lower esophagus and upper part of the stomach. The effects will be assessed three and six months after the procedure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Gastroesophageal reflux disease (GERD) is common and many patients are dependent on daily use of proton pump inhibitors (PPIs). The goal of this small clinical trial is to examine the effect of endoscopic treatment of GERD by mucosal band ligation.
Patients (n=12) with GERD satisfying inclusion and exclusion criteria will be invited to participate and the degree of gastroesophageal reflux will be assessed before treatment, and three and six months after the procedure. The results of the trial will be used to plan a larger study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Endoscopic mucosal band ligation All 12 patients with GERD will undergo the same procedure. Multiple rubber bands will be used to ligate mucosa in the gastroesophageal junction and cardia in 3/4 of the circumference. |
Other: Endoscopic mucosal band ligation
The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
|
Outcome Measures
Primary Outcome Measures
- Change from baseline esophageal 24 hour pH/impedance at 3 months [3 months]
Esophageal pH/impedance will be measured by a catheter left in place for 24 hours
- Change from baseline esophageal 24 hour pH/impedance at 6 months [6 months]
Esophageal pH/impedance will be measured by a catheter left in place for 24 hours
- Change from baseline symptoms of gastroesophageal reflux at 3 months [3 months]
GERD Q score. Gastroesophageal reflux disease Questionnaire with minimum value 0 (no symptoms) and maximum value 18 (severe symptoms)
- Change from baseline symptoms of gastroesophageal reflux at 6 months [6 months]
GERD Q score. Gastroesophageal reflux disease Questionnaire with minimum value 0 (no symptoms) and maximum value 18 (severe symptoms)
- Change from baseline in use of proton pump inhibitors (PPI) at 3 months [3 months]
PPI use (number of days PPI was used during the period 7-14 days before the 3 months visit)
- Change from baseline in use of proton pump inhibitors (PPI) at 6 months [6 months]
PPI use (number of days PPI was used during the period 7-14 days before the 6 months visit)
- Adverse events during the study period of 6 months [6 months]
Adverse events or complications of the treatment will be registered during the study period
Secondary Outcome Measures
- Change from baseline in dysphagia at 3 months [3 months]
Dysphagia assessed by Marks score. The minimum value is 0 (no dysphagia) and the maximum value is 6 (can not eat, which is the most severe symptom).
- Change from baseline in dysphagia at 6 months [6 months]
Dysphagia assessed by Marks score. The minimum value is 0 (no dysphagia) and the maximum value is 6 (can not eat, which is the most severe symptom).
- Change from baseline in Hills flap valve at 3 months [3 months]
The Hills flap valve assessed during endoscopy. Minimum value is 1 (good function) and the maximum value is 4 (poor function)
- Change from baseline in Hills flap valve at 6 months [6 months]
The Hills flap valve assessed during endoscopy. Minimum value is 1 (good function) and the maximum value is 4 (poor function)
Eligibility Criteria
Criteria
Inclusion Criteria (both criteria must be fulfilled):
-
GERD. GERD must be diagnosed by either endoscopic esophagitis or esophageal pH measurement with DeMeester score > 14.72 and pH <4 more than 4% of a 24-h period and symptom association probability (SAP) > 95%
-
Subjective insufficient symptom control with PPI therapy once daily or intolerance to PPI or desire to stop PPI treatment and therefore willingness to undergo endoscopic treatment.
Exclusion Criteria:
-
Hiatal hernia > 2 cm
-
Age < 18_years
-
Previous esophageal or gastric surgery,
-
Preexisting esophageal stricture
-
Anti-coagulant medication
-
Use of platelet inhibitors other than acetylsalicylic acid
-
Manometric indication of motility disorder
-
Connective tissue diseases
-
BMI > 30
-
Chronic liver disease
-
Coronary heart disease
-
Chronic obstructive pulmonary disease
-
Other significant comorbidity
-
Indication for long-term PPI use other than GERD
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | St.Olavs Hospital | Trondheim | Norway | 7030 |
Sponsors and Collaborators
- St. Olavs Hospital
Investigators
- Study Director: Gunnar Qvigstad, MD, PhD, St. Olavs Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 490996/2022